Thymulin
Also called FTS, Serum thymic factor
No single human route established in this referenceHuman study reference
Research reference
Human study · different product
Historical synthetic serum thymic factor report
IV synthetic FTS; exact amount and frequency are not specified in the indexed abstract
IgA changes reported within 4 weeks
Bordigoni et al., Lancet (1982)—historical FTS ↗When results may show
Thymulin
Evidence gap- When change was measured
- An uncontrolled three-child report does not establish reliable infection prevention, a general immune-benefit timeline or a wellness course.
- When to assess
- IgA changes reported within 4 weeks
- Conditions and limitations
- Three children with specific immune deficiencies; not healthy adults. The historical synthetic FTS preparation does not verify a retail zinc-bound thymulin product. Thymalin and thymosin alpha-1 are also different materials. No amount or cycle is invented.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Modelled level — every other day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 3hours
- Administrations
- 3.5/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Averaged over two weeks
Where these numbers come from
- Bordigoni et al., Lancet (1982)—historical FTSThe historical synthetic FTS preparation does not verify a retail zinc-bound thymulin product. Thymalin and thymosin alpha-1 are also different materials. No amount or cycle is invented.